sHER-2 Human ELISA

Notice

Restriction of a minimal quantity of 5 kits per order may apply.

Research topic

Oncology

Storage/Shipping

Store kit reagents between 2–8°C except controls. Store lyophilized controls at –20°C.

Summary

The human HER-2 gene encodes a putative transmembrane growth factor receptor (p185 protein) that is closely related to the epidermal growth factor receptor protein. The HER-2 gene product is a 185 kDa glycoprotein that contains an extracellular ligand-binding domain and intracellular tyrosine kinase activity. HER-2 protein staining is observed only in low levels in epithelial cells of most organs in normal human tissues and at slightly higher levels in fetal tissues. HER-2 protein is useful in identifying cancer cells with increased aggressiveness.

Assay format

Sandwich ELISA, HRP-labelled antibody

Sample requirements

100 µl (1:20 prediluted)

Applications

Amniotic fluid, Cell culture supernatant, Plasma-EDTA, Plasma-Heparin, Serum

Calibration Curve

Calibration range

0.6–10 ng/ml

Limit of detection

0.06 ng/ml

Limit of quantification

1.2 ng/ml

Intra-assay

CV = 1.9 %

Inter-assay

CV = 5.8 %

Spiking Recovery

89 %

Dilution Linearity

95 %

References to summary

• al-Kasspooles M, Moore JH, Orringer MB, Beer DG. Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int J Cancer. 1993 May 8;54 (2):213-9
• Ohguri T, Sato Y, Koizumi W, Saigenji K, Kameya T. An immunohistochemical study of c-erbB-2 protein in gastric carcinomas and lymph-node metastases: is the c-erbB-2 protein really a prognostic indicator?. Int J Cancer. 1993 Jan 2;53 (1):75-9
• Sato K, Moriyama M, Mori S, Saito M, Watanuki T, Terada K, Okuhara E, Akiyama T, Toyoshima K, Yamamoto T, et al.. An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer. 1992 Nov 15;70 (10):2493-8
• Heatley M, Maxwell P, Whiteside C, Toner PG. C-erbB-2 oncogene product expression depends on tumour type and is related to oestrogen receptor and lymph node status in human breast carcinoma. Pathol Res Pract. 1993 Apr;189 (3):261-6
• Paterson MC, Dietrich KD, Danyluk J, Paterson AH, Lees AW, Jamil N, Hanson J, Jenkins H, Krause BE, McBlain WA, et al.. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res. 1991 Jan 15;51 (2):556-67
• Ye DW, Zheng JF, Qian SX, Ma YJ. Correlation between the expression of oncogenes ras and c-erbB-2 and the biological behavior of bladder tumors. Urol Res. 1993 Jan;21 (1):39-43
• Tsai CM, Chang KT, Perng RP, Mitsudomi T, Chen MH, Kadoyama C, Gazdar AF. Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J Natl Cancer Inst. 1993 Jun 2;85 (11):897-901
• Kynast B, Binder L, Marx D, Zoll B, Schmoll HJ, Oellerich M, Schauer A. Determination of a fragment of the c-erbB-2 translational product p185 in serum of breast cancer patients. J Cancer Res Clin Oncol. 1993;119 (5):249-52
• Yu D, Wolf JK, Scanlon M, Price JE, Hung MC. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res. 1993 Feb 15;53 (4):891-8
• Paakko P, Nuorva K, Kamel D, Soini Y. Evidence by in situ hybridization that c-erbB-2 proto-oncogene expression is a marker of malignancy and is expressed in lung adenocarcinomas. Am J Respir Cell Mol Biol. 1992 Sep;7 (3):325-34
• Craven JM, Pavelic ZP, Stambrook PJ, Pavelic L, Gapany M, Kelley DJ, Gapany S, Gluckman JL. Expression of c-erbB-2 gene in human head and neck carcinoma. Anticancer Res. 1992 Nov-Dec;12 (6B):2273-6
• Wright C, Angus B, Nicholson S, Sainsbury JR, Cairns J, Gullick WJ, Kelly P, Harris AL, Horne CH. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res. 1989 Apr 15;49 (8):2087-90
• Stenman G, Sandros J, Nordkvist A, Mark J, Sahlin P. Expression of the ERBB2 protein in benign and malignant salivary gland tumors. Genes Chromosomes Cancer. 1991 Mar;3 (2):128-35
• Seidman JD, Frisman DM, Norris HJ. Expression of the HER-2/neu proto-oncogene in serous ovarian neoplasms. Cancer. 1992 Dec 15;70 (12):2857-60
• Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol. 1989 Aug;7 (8):1120-8
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987 Jan 9;235 (4785):177-82
• Dittadi R, Donisi PM, Brazzale A, Marconato R, Spina M, Gion M. Immunoenzymatic assay of erbB2 protein in cancer and non-malignant breast tissue. Relationships with clinical and biochemical parameters. Anticancer Res. 1992 Nov-Dec;12 (6B):2005-10
• Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P, et al.. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 1990 Jul 1;50 (13):4087-91
• Kern JA, Schwartz DA, Nordberg JE, Weiner DB, Greene MI, Torney L, Robinson RA. p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res. 1990 Aug 15;50 (16):5184-7
• Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinger J, Lippman ME, King CR. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol. 1990 Jan;8 (1):103-12
• Takamura Y, Miyoshi Y, Taguchi T, Noguchi S. Prediction of chemotherapeutic response by Technetium 99m--MIBI scintigraphy in breast carcinoma patients. Cancer. 2001 Jul 15;92 (2):232-9
• Osaki A, Toi M, Yamada H, Kawami H, Kuroi K, Toge T. Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients. Am J Surg. 1992 Oct;164 (4):323-6
• Rubin SC, Finstad CL, Wong GY, Almadrones L, Plante M, Lloyd KO. Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis. Am J Obstet Gynecol. 1993 Jan;168 (1 Pt 1):162-9
• Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al.. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989 May 12;244 (4905):707-12
• Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Bloom KJ. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist. 2003;8 (4):307-25
• Maguire HC Jr, Greene MI. The neu (c-erbB-2) oncogene. Semin Oncol. 1989 Apr;16 (2):148-55